



June 23, 2025

OTC Markets Group, Inc.
304 Hudson Street, 2nd Floor
New York, NY 10013

Re: BIG SCREEN ENTERTAINMENT GROUP INC. ANNUAL REPORT FOR THE FISCAL YEAR ENDED MARCH 31, 2025

Dear Sirs:

This firm acts as counsel to Big Screen Entertainment Group Inc. (the “Issuer”):

1. This letter is prepared in connection with the Issuer’s filing of an Annual Report for the fiscal year ended March 31, 2025 (“Annual Report”), which contain financial statements for the same period.
2. OTC Markets Group, Inc. is entitled to rely on this letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.
3. I am a U.S. resident and have been retained by the Issuer as corporate and securities counsel, including but not limited to, for the purpose of rendering this letter and related matters.
4. We have examined such corporate records and other documents and such questions of law as we consider necessary or appropriate for purposes of rendering the letter.
5. I am authorized to practice law in the State of Utah. The opinions expressed herein are limited to matters concerning the laws of the State of Utah and Delaware and the federal laws of the United States. We express no opinion as to the laws of the any other jurisdiction.
6. I am permitted to practice before the Securities and Exchange Commission (the “SEC”) and have not been prohibited from practice hereunder.
7. In connection with this letter, we (i) investigated such questions of law, (ii) examined originals or certified, conformed or reproduction copies of documents, and such other agreements, instruments, documents and records of the Issuer, such certificates of public officials and such other documents, and (iii) received such information from officers and representatives of the Issuer, as we have deemed necessary or appropriate for the purpose

of this letter. In all such examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, and the authenticity of original and certified documents submitted to us and the conformity to original documents of all copies submitted to us as conformed or reproduction copies. As to various questions of fact relevant to opinions expressed herein, we have relied upon, and assume the accuracy of, representations and warranties contained in the documents and certificates and oral or written statements and other information of or from representatives of the Issuer and others.


8. We have relied upon the Issuer's previously filed quarterly reports and annual reports, management discussions and analysis and Officer/Directors disclosure (collectively, the "Information").
9. To the best of our knowledge, as of the date of this letter, with the filing of the Annual Report, the Information (i) constitutes "adequate current public information" concerning the securities and the Issuer and "is available" within the meaning of the Rule 144(c)(2) under the Securities Act, (ii) includes all information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the Pink OTC Markets' Guidelines for Providing Adequate Current Information, which are located on the internet at www.pinksheets.com, and (iv) has been posted through the OTC Disclosure and News Service.
10. The person responsible for the preparation of the Company's financial statements was Kimberley Kates who is qualified to prepare the financial statements. The financial statements included with the Report have not been audited.
11. The Company's transfer agent is Colonial Stock Transfer which is registered with the SEC. The method used to confirm the number of outstanding shares of common stock set forth in the Information Statement was to contact the transfer agent and receive written confirmation as to the number of outstanding shares.
12. I have personally met with management of the Issuer and the directors of the Issuer, have reviewed the information published by the Issuer on the OTC Disclosure and News Service and discussed the information with management and the directors of the Issuer.
13. To the best of my knowledge, after inquiry of management and the board of directors of the Issuer, neither the Issuer, any 5% holder of the securities in the Issuer nor any members of my firm are currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.
14. The opinions expressed herein are solely for the benefit of the OTC Market Groups, Inc., which is entitled to rely upon this letter, and may not be relied on in any manner or for any purpose by any other person or entity and may not be quoted in whole or in part without our prior written consent. We hereby grant OTC Markets Group, Inc. full and

complete permission and rights to publish this letter through the OTC Disclosure and News Service for viewing by the public and regulators.

15. To the best of our knowledge, after inquiry of management and the directors of the Company, no officer, director or 5% or greater holder of the outstanding securities of the Company, or counsel, is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.
16. Neither the Issuer nor its predecessors, is or ever was a "shell company" as defined in Rule 405 of the Securities Act and 12b-2 of the Exchange Act.
17. We have not received, nor do we have an agreement to receive in the future, shares of the Company's stock, in payment of services.
18. The opinions expressed herein are given as of the date hereof, and we undertake no obligation to supplement this letter if any applicable laws change after the date hereof or if we become aware of any facts that might change the opinions expressed herein after the date hereof or for any other reason.
19. No person other than OTC Markets Group, Inc. is entitled to rely on this letter. However, the undersigned hereby grants OTC Markets Group, Inc. full and complete permission and rights to publish this letter in the OTC Disclosure and News Service for viewing by the public and regulators.

Very Truly Yours,

Kunzler Bean & Adamson



J. Martin Tate, Esq.

KUNZLER BEAN & ADAMSON